NICE Positive for Ogsiveo (nirogacestat) for treating desmoid tumours – Merck Serono

Nirogacestat can be used, within its marketing authorisation, as an option to treat progressing desmoid tumours that need systemic treatment in adults.
Nirogacestat can only be used if the company provides it according to the commercial arrangement.

Why the committee made this recommendation: Usual treatment for progressing desmoid tumours that need systemic treatment is non-curative and aims to manage symptoms. This can include chemotherapy, which is not licensed for treating desmoid tumours. Clinical trial evidence shows that nirogacestat increases how long people have before their condition gets worse compared with placebo. Nirogacestat has not been directly compared with chemotherapy in a clinical trial. Indirect comparisons suggest that nirogacestat is likely to work as well as chemotherapy, but this is uncertain. The cost-effectiveness estimates are within the range that NICE considers an acceptable use of NHS resources.

So, nirogacestat can be used.